Vaccinex to delist Common Stock from Nasdaq; suspended since Dec 18, 2024; aiming a differentiated approach in treating neurodegenerative diseases.
On March 07, 2025, in Rochester, New York, Vaccinex, Inc. (OTC: VCNX) revealed its plan to remove its common stock from the Nasdaq. The clinical-stage biotech firm focuses on tackling neurodegenerative diseases by targeting astrogliosis and neuroinflammation via SEMA4D inhibition. The stock's Nasdaq trading halt commenced on December 18, 2024.